CERo Therapeutics Holdings, Inc. (CERO)
$
0.45
-0.07 (-15.56%)
Key metrics
Financial statements
Free cash flow per share
-1.5041
Market cap
4 Million
Price to sales ratio
3.4333
Debt to equity
-4.1489
Current ratio
0.7339
Income quality
0.5107
Average inventory
0
ROE
6.6104
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
CERo Therapeutics Holdings, Inc., an innovative immunotherapy company based in South San Francisco, California, focuses on advancing the development of engineered T cell therapeutics for cancer treatment. The operating expenses amount to $16,198,036.00 encompassing various operational costs incurred. In terms of financial performance, the company reported an income before tax of -$11,089,000.00 showcasing its pre-tax profitability. An interest expense of $0.00 was also incurred, reflecting its debt servicing obligations. The financial data pertains to the fiscal year 2024 and the company reported selling, general, and administrative expenses of $9,118,292.00 indicating its operational overhead costs. This highlights the company's commitment to managing costs while pursuing its promising therapeutic advancements in hematologic malignancies, particularly targeting an Eat Me signal upregulated on B cell and myeloid tumors. Investors may find the company intriguing, as the stock is affordable at $0.52 suitable for budget-conscious investors. It has a high average trading volume of 1,922,982.00 indicating strong liquidity in the market. With a market capitalization of $3,439,411.00 the company is classified as a small-cap player, which often presents unique investment opportunities. As a key player in the Biotechnology industry, it contributes significantly to the overall market landscape, driving forward innovative solutions in cancer immunotherapy. Moreover, it belongs to the Healthcare sector, which is recognized for fostering innovation and growth, positioning CERo Therapeutics favorably among its peers and enhancing its potential for success in the evolving field of cancer treatment.
Is CERo Therapeutics Holdings, Inc. (CERO) a good investment?
Investing in CERo Therapeutics Holdings, Inc. (CERO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is CERo Therapeutics Holdings, Inc. (CERO)'s stock forecast?
Analysts predict CERo Therapeutics Holdings, Inc. stock to fluctuate between $0.43 (low) and $102 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is CERo Therapeutics Holdings, Inc.'s market capitalization?
As of 2025-05-30, CERo Therapeutics Holdings, Inc.'s market cap is $3,439,411, based on 7,722,072 outstanding shares.
How does CERo Therapeutics Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, CERo Therapeutics Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy CERo Therapeutics Holdings, Inc. (CERO) stock?
To buy CERo Therapeutics Holdings, Inc. (CERO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CERO. Place an order (Market, Limit, etc.).
What is the best time to invest in CERo Therapeutics Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has CERo Therapeutics Holdings, Inc. stock ever split?
CERo Therapeutics Holdings, Inc.'s last stock split was 1:100 on 2025-01-08.
How did CERo Therapeutics Holdings, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.22 | Growth: 219,900%.
Where can I find CERo Therapeutics Holdings, Inc.'s investor relations reports?
Visit https://www.cero.bio/investor-relations for detailed financial reports.
Where can I find historical stock prices for CERo Therapeutics Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for CERo Therapeutics Holdings, Inc. stock?
All-time high: $1,238 (2024-02-15) | All-time low: $0.43 (2025-05-30).
What are the key trends affecting CERo Therapeutics Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a day ago
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evaluations SOUTH SAN FRANSCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the first patient in its Phase 1 clinical trial of CER-1236.
globenewswire.com
23 days ago
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million (the “Equity Rule”)
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute (SCRI), in Nashville, Tennessee, is a clinical trial site for the Company's Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting a poster at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill.
globenewswire.com
a month ago
SOUTH SAN FRANSCISCO, Calif, April 24, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado will be a key clinical trial site for the Company's Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region's leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway with first dosing of the initial cohort of patients expected by June.
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.
globenewswire.com
2 months ago
Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office (USPTO), which materially expands the Company's intellectual property portfolio. Patent Application No.
globenewswire.com
2 months ago
SOUTH SAN FRANSCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces its first clinical trial site for the Company's Phase 1 clinical trial of CER-1236. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.
globenewswire.com
2 months ago
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received clearance by the U.S. Food and Drug Administration (FDA) for a second Investigational New Drug (IND) application for lead compound CER-1236 for a Phase 1 clinical trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.
globenewswire.com
2 months ago
Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025
See all news
